HLBPEP Chairman Jin Yang-gon Acquires 22,000 Shares on Open Market

Jin Yang-gon, Chairman of HLB Group, has acquired shares of HLBPEP through on-the-market purchases.

According to HLBPEP on August 20, Chairman Jin purchased 22,000 shares of the company on the open market between August 12 and 19. This move is interpreted as reflecting his confidence in HLBPEP’s growth potential and future corporate value.

Earlier this year, including the recent purchase of HLBPEP shares, Chairman Jin has made a total of 51 rounds of on-the-market purchases of shares in various affiliates, including HLBNOVATION, HLBNANOGEN, HLBTHERAPEUTICS, HLBGENEX, and HLBBIOSTEP. The cumulative volume of affiliate shares acquired in 2026 alone has exceeded 1 million shares.

HLBPEP continues to expand its peptide API portfolio based on its accumulated technological expertise and production capabilities in the domestic peptide field. At the same time, the company is broadening its business scope through its global CDMO operations and new drug development, thereby strengthening its foundation for growth.

In particular, HLBPEP is continuously pursuing production facility automation and process optimization to enhance its competitiveness in peptide manufacturing. Centered on its Osong plant, the company is upgrading its production and quality management systems to meet global standards, while also bolstering its capabilities in large-scale synthesis and advanced purification to expand its foundation for entering the global CDMO market.

Overseas business achievements have also continued. Recently, the company completed registration of its vasopressin active pharmaceutical ingredient (API) on the U.S. Food and Drug Administration (FDA) Drug Master File (DMF) list, and signed a CDMO contract with a Japanese peptide specialist company for functional peptide development and production, thus initiating a full-scale expansion of its global business.

An HLBPEP official stated, “This recent stock purchase by Chairman Jin is regarded as a demonstration of trust in the company’s peptide technology and its mid- to long-term growth potential. In line with the growth of the global peptide market, we will continue to strengthen the competitiveness of our API and CDMO businesses, and expand into new fields such as drug development to further enhance our corporate value.”

This content was produced with the assistance of AI translation services.